Soliton completes second generation device further enhancing aesthetic capabilities
Achieves acoustic output twice as powerful as the first generation, potentially expanding market opportunity
HOUSTON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Soliton, Inc. (“Soliton” or the “Company”), a medical technology company that has developed a new acoustic shockwave device, today announced that it has built a second generation device that is potentially capable of delivering treatment for cellulite reduction, tattoo removal and other future indications. The device will be used in clinical trials and will require premarket clearance by the FDA prior to commercialization.
Dr. Chris Capelli, CEO of Soliton, explained “This is a tremendous step forward for our technology that allows us to target not only tattoo removal but also cellulite reduction. Our second generation device is now a platform technology that provides healthcare professionals with the flexibility to potentially to treat multiple indications with a single device by simply changing the replaceable single treatment cartridge.”
The second generation Rapid Acoustic Pulse (‘RAP”) device may be capable of treating both tattoos and cellulite conditions. In order to properly target cellulite, the device needed to be capable of running a specifically designed cartridge which required a runtime 20 times longer than the tattoo removal cartridge and a customized waveform which would penetrate deeper into the skin. Further, the device needed to impart acoustic output twice as powerful as that used to remove tattoos in order to potentially treat cellulite and other fibrotic disorders, such as keloid scarring. We believe this more powerful device may also be better suited to assist existing fat reduction technologies. The second generation technology allows different therapies to be delivered by simply changing out the replaceable cartridge on the same device.
Soliton is a medical device company focused on the development of a new form of acoustic shockwave (“Rapid Acoustic Pulse” or “RAP”) that the Company’s own recent clinical trials have shown to achieve tattoo removal results in 2-3 treatments versus the industry average of 10 or more with a stand-alone laser. Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth. Importantly, we believe these potential indications could position Soliton RAP as a stand-alone device, without the need for lasers or other procedures. The Company has initiated a proof of concept study in humans for the treatment of cellulite and has collaborated with a large global aesthetics company in a clinical study to determine if the RAP technology can improve their fat reduction technology. These clinical trials are in early stages and there is no guarantee that any specific outcome will be achieved.
Soliton is currently engaged in an Initial Public Offering to list its common stock on Nasdaq Capital Markets under the ticker symbol “SOLY,” pursuant to an offering circular (File No. 024-10854), which was qualified on November 27, 2018. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Being qualified by the Securities and Exchange Commission (“SEC”), does not mean that the SEC has approved, passed upon the merits, or passed upon the accuracy or completeness of the information. To learn more about this offering, please go see Soliton’s offering circular which may be found at the following location:
https://www.sec.gov/Archives/edgar/data/1548187/000162827918000315/soliton253g2.htm, or through Boustead via the website, www.flashfunders.com/soliton or by contacting Boustead at 6 Venture, Suite 265, Irvine, CA 92618 USA, tel. +1 949 502 4408 or by email at Offerings@Boustead1828.com.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The Company expects to file for premarket clearance with the U.S. Food and Drug Administration ("FDA") for its’ first device in the first quarter of 2019 and expects to receive clearance to market the device in mid 2019. This initial filing is limited to the Company’s device used in conjunction with the 1064 nm Q-switched laser to enable effective multiple pass laser treatments in a single office session to accelerate removal of black tattoos on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals. While the Company believes its’ technology has many potential applications, the Company has initially focused on the removal of tattoos, where both animal and human studies have shown promising results. The current standard of care for tattoo removal is to use a Q-switched (pulsed) laser to ablate the tattoo ink particles into pieces small enough for the body’s natural processes to remove them. Unfortunately, this current method is highly inefficient, requiring up to 10 or more office visits to achieve acceptable results. A clinical trial has demonstrated that using the Company’s RAP device, in conjunction with a Q-switched laser, has the potential to produce similar results in just 2 to 3 office visits. The Company believes this “Soliton” method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods.
For more information about the Company, please visit: http://www.soliton.com
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton RAP to accelerate tattoo fading, fat removal and/or cellulite reduction and the ability of Soliton to complete an IPO. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" and elsewhere in our offering circular. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
An investment in Soliton, Inc. has risks as Soliton can make no assurances about the success of its products, licensing or marketing efforts, consequently, investors in Soliton Inc. may lose some or all of their investments.
|CONTACT:||Joe Dorame, Joe Diaz & Robert Blum|
|Lytham Partners, LLC|
Released February 7, 2019